Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2015 Sep 21;5:21. doi: 10.1186/s13569-015-0036-9

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Brohl et al. 2015

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

PMC Copyright notice

Fig. 2 — PET/CT imaging prior to (a–d) and after 10 weeks (e–h) of sunitinib therapy. Prior to treatment, whole body PET (a) revealed a large hypermetabolic lesion in the dome of the liver, a PET-avid sub-cm L hepatic lesion, and hypermetabolic activity in the abdominal wall near the site of previous surgical resection. On cross sectional CT imaging (b) the large hepatic lesion measured 5.9 × 5.1 cm in maximal dimension, and the corresponding area on PET imaging (c) and fused PET/CT (d) revealed an SUV_max of 8.4. Both liver lesions were no longer detectable on repeat imaging (e–h), and the surgical site hypermetabolic activity decreased (e), consistent with resolving post-operative changes